Core Viewpoint - The Guangdong Securities Regulatory Commission has uncovered multiple financial fraud activities by 聚石化学, including inaccurate revenue accounting, undisclosed related party transactions, and inadequate internal controls [2][4]. Group 1: Financial Misconduct - 聚石化学 engaged in false trade activities through its subsidiary, 广东冠臻科技, resulting in inflated revenues of 86,550,865.69 yuan and inflated costs of 88,238,071.82 yuan, leading to a profit reduction of 1,687,206.13 yuan [2][3]. - Another fraudulent trade involved the company participating in a third-party trade chain, inflating both revenue and costs by 52,236,440.86 yuan, without any actual commercial substance [3]. - The company also reported inflated revenue of 18,020,070.80 yuan and costs of 17,995,752.21 yuan from sales of isooctane, which did not involve actual goods being shipped [3]. Group 2: Regulatory Actions and Penalties - The Guangdong Securities Regulatory Commission has mandated corrective actions, issued warnings, and imposed a fine of 2.4 million yuan on 聚石化学, along with penalties totaling 4.3 million yuan on four executives involved [3][4]. - The company has been ordered to improve its internal controls and enhance the quality of information disclosure to prevent future misconduct [4]. Group 3: Impact on Business and Future Outlook - 聚石化学's acquisition of 冠臻科技 has turned out to be unsuccessful, with the latter's performance deteriorating significantly post-acquisition, leading to substantial losses for 聚石化学 [5][6]. - The company anticipates a net loss of between 90 million to 120 million yuan for 2025, a stark contrast to a profit of 23,614.68 million yuan in the previous year, primarily due to the impact of the international oil market and operational challenges [6][7]. - Despite divesting 冠臻科技, 聚石化学 continues to face difficulties in returning to pre-IPO performance levels, with ongoing challenges in its diversified business operations [7].

Core Viewpoint - JuShi Chemical is under regulatory investigation for suspected violations of information disclosure, raising concerns about its financial practices and potential fraud in its issuance process [2][8]. Financial Performance - The company experienced a significant decline in profit after its IPO, with total profit dropping from 238 million yuan in 2020 to 101 million yuan in 2021, a decrease of nearly 60% [3]. - For the first three quarters of 2022, the company reported a revenue of 2.963 billion yuan, a year-on-year decrease of 7.17%, and a net profit attributable to shareholders of only 5.7684 million yuan [3]. - The stock price has also declined from an IPO price of 36.65 yuan per share to 20.78 yuan per share as of November 25, 2022, indicating a state of loss [3]. Revenue Adjustments - In 2021, the company adjusted its revenue by over 200 million yuan, citing a shift from gross to net revenue recognition due to its role as an agent in trade transactions [4][5]. - In 2022, further adjustments were made, with nearly 400 million yuan being reclassified, as the company claimed it had control over the goods sold [5]. Audit Firm Changes - The company has changed its auditing firms multiple times, raising red flags about its financial oversight. The initial auditor was Guangdong Zhengzhong Zhujiang, followed by Lixin, and then Zhongxinghua [6]. - The current auditor, Zhongxinghua, faced regulatory penalties for non-compliance during the audit of JuShi Chemical's 2022 annual report [6]. Client Relationships and Transactions - Two major clients, Foshan Qizheng Technology Co., Ltd. and Foshan Tianhua Technology Co., Ltd., were involved in significant trade transactions with JuShi Chemical, but both companies were deregistered in February 2023 [9][10]. - The company engaged in stock transactions with shareholders of these clients, raising questions about the legitimacy of its business practices [13][15]. Regulatory Investigation - The regulatory investigation into JuShi Chemical is focused on potential fraudulent issuance and misleading financial disclosures, particularly concerning its revenue recognition practices and client relationships [2][8].